コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ion of extracellular space by calculation of extracellular volume fraction.
2 n to calculate global myocardial T1, T2, and extracellular volume fraction.
3 enhancement, native T1 relaxation times, and extracellular volume fraction.
4 portion to the square root of enlarged total extracellular volume fraction.
5 gression, leading to an apparent increase in extracellular volume fraction.
6 pattern of scar and quantify the myocardial extracellular volume fraction.
7 sis on the basis of assessment of myocardial extracellular volume fraction.
8 red ventriculo-arterial coupling, and higher extracellular volume fraction.
9 ement (LGE), T1 and T2 relaxation times, and extracellular volume fraction.
10 with the latter also associated with higher extracellular volume fraction.
11 and the extent of interstitial expansion via extracellular volume fraction.
12 en) exhibited increased myocardial fibrosis (extracellular volume fraction, 0.34 +/- 0.06 vs 0.29 +/-
13 adolinium enhancement, 0.90; T2 ratio, 0.79; extracellular volume fraction, 0.71; early gadolinium en
14 T1 (1225+/-30 to 1239+/-30 ms; P=0.02), and extracellular volume fraction (24.5+/-2.3% to 26.0+/-2.6
15 versus 1152+/-46 milliseconds; P<0.001) and extracellular volume fraction (26+/-5% versus 30+/-6%; P
16 ed regression led to an apparent increase in extracellular volume fraction (27.4+/-3.1% to 30.2+/-2.8
17 ly; P<0.001) and increased diffuse fibrosis (extracellular volume fraction, 27.4+/-2.2% versus 27.2+/
18 s; 95% CI: -69 to -5 ms; P = 0.026), indexed extracellular volume fraction (-3.9 g/m(2); 95% CI: -7.0
19 tauic), a cell size-dependent parameter, and extracellular volume fraction, a marker of interstitial
20 i) [adjusted z-score: 0.47 (0.09, 0.86)] and extracellular volume fraction [adjusted z-score: 0.79 (0
21 lar sodium concentration (C1, in mM) and the extracellular volume fraction (alpha) in grey and white
24 n the cellular compartment, while changes in extracellular volume fraction and tortuosity, which are
25 itudinal strain, and T1 mapping to determine extracellular volume fraction and volume of cellular and
27 ric-mapping subclinical fibrosis (native-T1, extracellular volume fraction) and inflammation/edema (m
28 tification using native T1 relaxation times, extracellular volume fraction, and global longitudinal s
29 endently associated with wall thickness, T2, extracellular volume fraction, and late gadolinium enhan
30 l size, vascular volume fraction, intra- and extracellular volume fractions, and pseudo-diffusivity a
31 fraction, thus confirming the suitability of extracellular volume fraction as an in vivo measure of d
32 resonance measures of interstitial fibrosis (extracellular volume fraction), as well as serum biomark
33 High LV mass index, low native T1, and low extracellular volume fraction at baseline were all predi
35 Both post-contrast myocardial T1 time and extracellular volume fraction correlated with beta, the
36 ise CMR parameters, global myocardial T1 nor extracellular volume fraction differed significantly bet
37 c resonance (CMR) measurements of myocardial extracellular volume fraction (ECV) and late gadolinium
38 sodium concentration ([Formula: see text]), extracellular volume fraction (ECV) and the water fracti
41 gadolinium enhancement (LGE), and automated extracellular volume fraction (ECV) maps per patient wer
43 s through late gadolinium enhancement (LGE), extracellular volume fraction (ECV) measures by cardiac
45 rdiac MRI T1 mapping sequences for measuring extracellular volume fraction (ECV) throughout the spect
46 d cardiac magnetic resonance measurements of extracellular volume fraction (ECV) to discover and quan
51 sis for native T1 relaxation times, GLS, and extracellular volume fraction (ECV) with respect to mort
52 ardiovascular risk factors on myocardial T1, extracellular volume fraction (ECV), and T2 at 3T in the
53 arditis as well as native T1, calculation of extracellular volume fraction (ECV), and T2 mapping (onl
54 ques permit quantification of the myocardial extracellular volume fraction (ECV), representing a surr
59 um enhancement [LGE], T1 and T2 mapping, and extracellular volume fraction [ECV] z scores) of patient
60 arker), native/postcontrast T1 mapping (with extracellular volume fraction [ECV]) to assess edema and
61 available indices of interstitial fibrosis (extracellular volume fraction [ECV]; N = 1172 and native
62 ocardial native (n) T1 (fibro-inflammation), extracellular volume fraction (fibrosis), and triglyceri
63 T2>52 ms, 78% for native T1>981 ms, 74% for extracellular volume fraction >0.24, and 100% for T2 rat
64 ighted imaging in 2 patients (13%), elevated extracellular volume fraction in 3 patients (20%), and e
66 es a significant increase of skeletal muscle extracellular volume fraction in study participants with
69 tricular dysfunction and prevented increased extracellular volume fraction, indicating that T1 mappin
70 s not affect either the TMA diffusion or the extracellular volume fraction, indicating that the enzym
72 between HCM and hypertension, over and above extracellular volume fraction, LV wall thickness and ind
73 pertrophy to establish whether native T1 and extracellular volume fraction may complement electrocard
74 nterstitium and quantify ECM expansion using extracellular volume fraction measures and other derange
77 BNP was associated with a 0.62% increment in extracellular volume fraction (p < 0.001), 0.011 increme
78 stant (P = .0007) and 14.3% in extravascular-extracellular volume fraction (P = .002) were seen after
80 lation results indicate that even for larger extracellular volume fractions than what is reported for
81 For two different geometries with the same extracellular volume fraction the geometry with the most
82 olume transfer coefficient K(trans), and the extracellular volume fraction v(e) were calculated for t
83 rd CMR parameters, global myocardial T1, and extracellular volume fraction values for assessing the a
84 longitudinal strain post-AVR, an increase in extracellular volume fraction was associated with worsen